Bleakley Financial Group LLC Grows Stake in Hologic, Inc. (NASDAQ:HOLX)

Bleakley Financial Group LLC lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 23.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,368 shares of the medical equipment provider’s stock after purchasing an additional 1,227 shares during the period. Bleakley Financial Group LLC’s holdings in Hologic were worth $519,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of HOLX. Mather Group LLC. purchased a new stake in Hologic in the first quarter worth $48,000. Ballentine Partners LLC increased its holdings in Hologic by 7.4% in the 1st quarter. Ballentine Partners LLC now owns 3,941 shares of the medical equipment provider’s stock worth $307,000 after acquiring an additional 273 shares during the last quarter. Toth Financial Advisory Corp raised its stake in Hologic by 81.1% in the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 347 shares during the period. Hennion & Walsh Asset Management Inc. raised its stake in Hologic by 3.0% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 17,674 shares of the medical equipment provider’s stock valued at $1,378,000 after acquiring an additional 509 shares during the period. Finally, Diversified Trust Co purchased a new stake in Hologic during the first quarter valued at about $1,286,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 0.5 %

Shares of HOLX opened at $81.15 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67. The company has a market capitalization of $18.94 billion, a P/E ratio of 41.40, a P/E/G ratio of 2.89 and a beta of 0.98. The firm’s 50 day simple moving average is $80.94 and its 200 day simple moving average is $77.74.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.93 EPS. Sell-side analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Evercore ISI lifted their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. boosted their target price on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Royal Bank of Canada restated a “sector perform” rating and set a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. StockNews.com cut Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. Finally, Stephens reiterated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.50.

Insider Activity at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.